Novaspira Biotherapeutics Announces Late-Breaking Oral Presentation of First-in-Human Data for BOS-342 (NS-342), a Novel GPC3 × 4-1BB Bispecific at SITC 2026
CHATHAM, NJ, UNITED STATES, October 29, 2026 /EINPresswire.com/ — NovaSpira Biotherapeutics today announced that a Late Breaking Abstract (LBA) from its Phase I clinical program evaluating BOS 342 (NS-342), a novel GPC3 × 4 1BB bispecific molecule, has been selected for an oral presentation at the Society for Immunotherapy of Cancer (SITC) 41st Annual Meeting, taking place November 6–8, 2026 in Phoenix, Arizona.
Presentation details
• Title: A Phase I First-in-Human Study of BOS-342, a novel GPC3 × 4-1BB Bispecific Molecule, in Advanced Hepatocellular Carcinoma: Early Report of Safety, Immune, Biochemical and Durable Clinical Responses
• Abstract number: 1173 (Late-Breaking Abstract)
• Session: Clinical Oral Abstract Session 2
• Date and time: Saturday, November 7, 2026, 1:45 PM (local time)
• Presenter: Hong Jae Chon, M.D., Ph.D., CHA Bundang Medical Center, Seongnam, Republic of Korea
NovaSpira looks forward to participating in SITC 2026 and sharing information about the BOS 342 (NS-342) program with the scientific and clinical community. In accordance with SITC’s embargo policy, scientific data and results from the study will be released when the official abstract embargo lifts on November 6, 2026 at 9:00 AM ET.
About NS-342
NS-342 (formerly PRS-342, BOS-342) is a novel GPC3 × 4-1BB bispecific protein. Preclinical data has shown potent T-cell activation and tumor cell lysis that are strictly dependent on the presence of GPC3-positive tumor cells; increased production of IL-2, a pro-inflammatory cytokine associated with anti-tumor immune response; TIL infiltration in tumors in HCC Xenograft mice; and potent anti-tumor activities (1).
About NovaSpira Biotherapeutics, Inc.
NovaSpira Biotherapeutics is a clinical stage biotechnology company developing next generation immunotherapies for solid tumors with high unmet need. NS 342, the lead candidate, is in Phase 1 clinical development as a bispecific T cell and immune cell activator therapy for GPC3 positive solid tumors, including liver and lung cancers. For more information, visit www.novaspirabio.com
Cautionary Statement Regarding Forward-Looking Statements
Statements in this press release that are not purely historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. We use words such as “commitment,” “advancing,” “believe,” “potential,” and similar expressions to identify these forward-looking statements. These forward-looking statements are based on NovaSpira’s current expectations and involve assumptions that may never materialize or may prove to be incorrect; consequently, actual results may differ materially from those expressed or implied due to a number of factors, including risks related to NovaSpira’s ability to grow and advance its pipeline and execute on its business plan; and other risks and uncertainties inherent in drug development. The forward-looking statements included in this press release are made only as of the date of this press release. Except as required by law, NovaSpira assumes no obligation and does not intend to update any forward-looking statements included in this press release.
——————————————————
1. Birgit Bossenmaier, Corinna Schlosser, Rachida-Siham Bel Aiba, Eva-Maria Hansbauer, Thomas Jaquin, Christian Barthels, Janet Peper, Markus Zettl, Benjamin Weiche, Costimulatory T-cell engagement by PRS-342, a GPC3/4-1BB bispecific molecule, leads to activation of T cells and tumor growth inhibition in a HCC humanized mouse model, AACR, 2019
Company Contact
Novaspira Biotherapeutics
info@novaspirabio.com
Legal Disclaimer:
EIN Presswire provides this news content “as is” without warranty of any kind. We do not accept any responsibility or liability
for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this
article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Media gallery
